Last edition
News about "Diffuse Large B-Cell Lymphoma (DLBCL)"
AbbVie Reports Positive Phase 3 Results for Epcoritamab in Diffuse Large B-Cell Lymphoma
AbbVie reported positive phase 3 results for epcoritamab plus lenalidomide, showing improved Progression-Free Survival (PFS) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
Diffuse Large B-Cell Lymphoma (DLBCL) | 01/07/2026 | By News Bureau
US FDA Accepts Roche's Lunsumio-Polivy Filing for Relapsed Large B-Cell Lymphoma
The US Food and Drug Administration (FDA) has accepted Roche’s supplemental Biologics License Application for the Lunsumio and Polivy combination in relapsed or refractory large B-cell lymphoma. The filing is supported by Phase 3 SUNMO study data showing a 59 percent reduction in the risk of disease progression or death.
Diffuse Large B-Cell Lymphoma (DLBCL) | 19/06/2026 | By News Bureau
AbbVie Receives FDA Approval for EPKINLY Combo in Relapsed/Refractory Follicular Lymphoma
AbbVie has secured FDA approval for EPKINLY in combination with rituximab and lenalidomide (EPKINLY + R2), marking the first bispecific antibody combo therapy available for patients with relapsed or refractory follicular lymphoma after at least one prior systemic treatment.
Diffuse Large B-Cell Lymphoma (DLBCL) | 19/11/2025 | By Dineshwori | 176
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy